Skip to content

Debt-to-equity at other companies

Opko Health logo
Opko HealthOPK
0.0×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-1.5×
Theravance Biopharma logo
Theravance BiopharmaTBPH
0.1×-0.2×
HRO
HarrowHROW
10.7×+2.6×
Precigen logo
PrecigenPGEN
4.9×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
0.0×

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$846.21M+16.3%
Enterprise value$831.61M+15.7%
P/S4.1×-4.8×

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Return on equity-147.9%
Current ratio2.2×-1.4×

Where this comes from

Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed August 10, 2023, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s debt-to-equity?
Phathom Pharmaceuticals, Inc. (PHAT) reported debt-to-equity of 5.6× in Q2 2023.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.